Uninterrupted anticoagulation with non-vitamin K antagonist oral anticoagulants in atrial fibrillation catheter ablation

Lessons learned from randomized trials

Rhanderson Cardoso, Stephan Willems, Edward P. Gerstenfeld, Atul Verma, Richard Schilling, Stefan H. Hohnloser, Ken Okumura, Matias Nordaby, Marc A. Brouwer, Hugh Calkins

Research output: Contribution to journalArticle

Abstract

Catheter ablation has been established as a rhythm control strategy in selected patients with atrial fibrillation (AF) who have failed or wish to avoid anti-arrhythmic drugs. Uninterrupted oral anticoagulation with vitamin K antagonists (VKAs) peri-ablation is associated with a lower risk of thromboembolic and bleeding complications as compared to interrupted oral anticoagulation and bridging heparin. However, a substantial portion of patients with AF are treated with non-vitamin K antagonist oral anticoagulants (NOACs). Herein, we perform an in-depth review and comparison of three recent randomized trials of uninterrupted oral anticoagulation with NOACs vs VKAs in patients undergoing AF catheter ablation. Furthermore, we report pooled results of these randomized trials. The pooled incidence of major bleeding was significantly lower with NOACs as compared to VKAs (2% vs 4.9%, respectively; odds ratio [OR] 0.40; 95% confidence intervals [CI] 0.16-0.99). Similarly, cardiac tamponade was also reduced in the NOAC group (0.4% vs 1.5%; OR 0.27; 95% CI 0.07-0.97). Thromboembolic complications were not significantly different between groups. Overall, these findings support the 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement's class I recommendation for uninterrupted NOAC use in patients undergoing AF catheter ablation.

Original languageEnglish (US)
JournalClinical Cardiology
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Catheter Ablation
Anticoagulants
Atrial Fibrillation
Vitamin K
Odds Ratio
Confidence Intervals
Hemorrhage
Vitamin K 2
Cardiac Tamponade
Anti-Arrhythmia Agents
Heparin
Incidence
Pharmaceutical Preparations

Keywords

  • apixaban
  • atrial fibrillation
  • catheter ablation
  • dabigatran
  • non-vitamin K antagonist oral anticoagulants
  • rivaroxaban
  • vitamin-K antagonist
  • warfarin

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Uninterrupted anticoagulation with non-vitamin K antagonist oral anticoagulants in atrial fibrillation catheter ablation : Lessons learned from randomized trials. / Cardoso, Rhanderson; Willems, Stephan; Gerstenfeld, Edward P.; Verma, Atul; Schilling, Richard; Hohnloser, Stefan H.; Okumura, Ken; Nordaby, Matias; Brouwer, Marc A.; Calkins, Hugh.

In: Clinical Cardiology, 01.01.2018.

Research output: Contribution to journalArticle

Cardoso, Rhanderson ; Willems, Stephan ; Gerstenfeld, Edward P. ; Verma, Atul ; Schilling, Richard ; Hohnloser, Stefan H. ; Okumura, Ken ; Nordaby, Matias ; Brouwer, Marc A. ; Calkins, Hugh. / Uninterrupted anticoagulation with non-vitamin K antagonist oral anticoagulants in atrial fibrillation catheter ablation : Lessons learned from randomized trials. In: Clinical Cardiology. 2018.
@article{4c469602c98c49d586d7842ad77aefc2,
title = "Uninterrupted anticoagulation with non-vitamin K antagonist oral anticoagulants in atrial fibrillation catheter ablation: Lessons learned from randomized trials",
abstract = "Catheter ablation has been established as a rhythm control strategy in selected patients with atrial fibrillation (AF) who have failed or wish to avoid anti-arrhythmic drugs. Uninterrupted oral anticoagulation with vitamin K antagonists (VKAs) peri-ablation is associated with a lower risk of thromboembolic and bleeding complications as compared to interrupted oral anticoagulation and bridging heparin. However, a substantial portion of patients with AF are treated with non-vitamin K antagonist oral anticoagulants (NOACs). Herein, we perform an in-depth review and comparison of three recent randomized trials of uninterrupted oral anticoagulation with NOACs vs VKAs in patients undergoing AF catheter ablation. Furthermore, we report pooled results of these randomized trials. The pooled incidence of major bleeding was significantly lower with NOACs as compared to VKAs (2{\%} vs 4.9{\%}, respectively; odds ratio [OR] 0.40; 95{\%} confidence intervals [CI] 0.16-0.99). Similarly, cardiac tamponade was also reduced in the NOAC group (0.4{\%} vs 1.5{\%}; OR 0.27; 95{\%} CI 0.07-0.97). Thromboembolic complications were not significantly different between groups. Overall, these findings support the 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement's class I recommendation for uninterrupted NOAC use in patients undergoing AF catheter ablation.",
keywords = "apixaban, atrial fibrillation, catheter ablation, dabigatran, non-vitamin K antagonist oral anticoagulants, rivaroxaban, vitamin-K antagonist, warfarin",
author = "Rhanderson Cardoso and Stephan Willems and Gerstenfeld, {Edward P.} and Atul Verma and Richard Schilling and Hohnloser, {Stefan H.} and Ken Okumura and Matias Nordaby and Brouwer, {Marc A.} and Hugh Calkins",
year = "2018",
month = "1",
day = "1",
doi = "10.1002/clc.23120",
language = "English (US)",
journal = "Clinical Cardiology",
issn = "0160-9289",
publisher = "John Wiley and Sons Inc.",

}

TY - JOUR

T1 - Uninterrupted anticoagulation with non-vitamin K antagonist oral anticoagulants in atrial fibrillation catheter ablation

T2 - Lessons learned from randomized trials

AU - Cardoso, Rhanderson

AU - Willems, Stephan

AU - Gerstenfeld, Edward P.

AU - Verma, Atul

AU - Schilling, Richard

AU - Hohnloser, Stefan H.

AU - Okumura, Ken

AU - Nordaby, Matias

AU - Brouwer, Marc A.

AU - Calkins, Hugh

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Catheter ablation has been established as a rhythm control strategy in selected patients with atrial fibrillation (AF) who have failed or wish to avoid anti-arrhythmic drugs. Uninterrupted oral anticoagulation with vitamin K antagonists (VKAs) peri-ablation is associated with a lower risk of thromboembolic and bleeding complications as compared to interrupted oral anticoagulation and bridging heparin. However, a substantial portion of patients with AF are treated with non-vitamin K antagonist oral anticoagulants (NOACs). Herein, we perform an in-depth review and comparison of three recent randomized trials of uninterrupted oral anticoagulation with NOACs vs VKAs in patients undergoing AF catheter ablation. Furthermore, we report pooled results of these randomized trials. The pooled incidence of major bleeding was significantly lower with NOACs as compared to VKAs (2% vs 4.9%, respectively; odds ratio [OR] 0.40; 95% confidence intervals [CI] 0.16-0.99). Similarly, cardiac tamponade was also reduced in the NOAC group (0.4% vs 1.5%; OR 0.27; 95% CI 0.07-0.97). Thromboembolic complications were not significantly different between groups. Overall, these findings support the 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement's class I recommendation for uninterrupted NOAC use in patients undergoing AF catheter ablation.

AB - Catheter ablation has been established as a rhythm control strategy in selected patients with atrial fibrillation (AF) who have failed or wish to avoid anti-arrhythmic drugs. Uninterrupted oral anticoagulation with vitamin K antagonists (VKAs) peri-ablation is associated with a lower risk of thromboembolic and bleeding complications as compared to interrupted oral anticoagulation and bridging heparin. However, a substantial portion of patients with AF are treated with non-vitamin K antagonist oral anticoagulants (NOACs). Herein, we perform an in-depth review and comparison of three recent randomized trials of uninterrupted oral anticoagulation with NOACs vs VKAs in patients undergoing AF catheter ablation. Furthermore, we report pooled results of these randomized trials. The pooled incidence of major bleeding was significantly lower with NOACs as compared to VKAs (2% vs 4.9%, respectively; odds ratio [OR] 0.40; 95% confidence intervals [CI] 0.16-0.99). Similarly, cardiac tamponade was also reduced in the NOAC group (0.4% vs 1.5%; OR 0.27; 95% CI 0.07-0.97). Thromboembolic complications were not significantly different between groups. Overall, these findings support the 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement's class I recommendation for uninterrupted NOAC use in patients undergoing AF catheter ablation.

KW - apixaban

KW - atrial fibrillation

KW - catheter ablation

KW - dabigatran

KW - non-vitamin K antagonist oral anticoagulants

KW - rivaroxaban

KW - vitamin-K antagonist

KW - warfarin

UR - http://www.scopus.com/inward/record.url?scp=85058011556&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058011556&partnerID=8YFLogxK

U2 - 10.1002/clc.23120

DO - 10.1002/clc.23120

M3 - Article

JO - Clinical Cardiology

JF - Clinical Cardiology

SN - 0160-9289

ER -